Krystal Biotech KRYS lawsuit and settlement news

Opinion · Devil's advocate

Fact-check-o-meter

Vyjuvek numbers hold up; the new Gorlin data are thinner than the release reads

Krystal's revenue and cash figures match its 10-Q, and the company flagged an earlier KB801 data point itself. The KB113 release leads with a lesion response rate built on three open-label patients, and the legal matters in the 10-Q, including DOJ subpoenas tied to Vyjuvek, were not in the quarterly results release.

1. Science · weight medium

   Headline response rate counts any shrinkage in 3 patients

   The company said: "Broad antitumor responses were detected in all three Gorlin syndrome patients treated with KB113, with over 80% of assessed BCC lesions reducing in size;" source

   The record says: The same release's table shows 69/83 (83.1%) lesions with "Any clinical regression in lesion size", 42/83 (50.6%) with more than 50% regression and 8/83 (9.6%) with at least 90% regression. It describes the study as "a multicenter, single-arm, open label study" in which "The investigator selected which landmark lesions to inject" and regression was judged on an "investigator-assessed 5-point clearance scale". source

   Our view: The 80% figure is true as stated, but it includes any shrinkage at all. About one lesion in ten reached 90% regression. With three patients, no control arm and the investigator both choosing and grading lesions, this is a first signal, not efficacy data.

2. Science · weight medium

   Histology confirmed response only in lesions already doing best

   The company said: "Complete clearance of an injected lesion was also confirmed histologically for each of the three patients treated with KB113." source

   The record says: The release explains: "To further assess clinical regression, one injected lesion from each patient that had achieved at least 90% clinical regression was biopsied." The release cites no registry entry for the Gorlin pilot study itself. The OPAL-1 record it points to (NCT05970497) covers the separate KB707 phase 1/2 solid tumor study and lists two primary outcomes, "Percentage of adverse events (AEs)" and "Percentage of serious adverse events (SAEs)", and an estimated enrollment of 240. source

   Our view: Three biopsies from the best-responding lesions show the drug can clear a tumor. They say little about how often it does. The OPAL-1 registry primary outcomes are safety only and the release gives no registry record for the Gorlin pilot, so the response analysis here is preliminary.

3. Press release vs filing · weight low

   $1.1 billion headline versus the 10-Q's narrower cash line

   The company said: "Cash, cash equivalents and investments totaled $1.1 billion as of June 30, 2026" source

   The record says: The 10-Q says: "As of June 30, 2026, our cash, cash equivalents and short-term investments balance was approximately $845.6 million". The balance sheet in the release lists $257,291 thousand of long-term investments on top of that. source

   Our view: Both numbers are right. The difference is long-term investments of about $257 million, which the 10-Q leaves out when it says the cash is enough for at least 12 months. The filing's 12-month funding statement uses the narrower $845.6 million figure.

4. Press release vs filing · weight low

   An earlier KB801 study surfaced through a patent filing

   The company said: "The Company continues to enroll in EMERALD-1, the Company's registrational, 1:1 randomized, double-masked, multicenter, placebo-controlled study evaluating KB801 for the treatment of NK." source

   The record says: A July 21 8-K says a patent response "included data from a patient who received KB801 in a discontinued clinical study" and that "The Company did not previously disclose the single-patient observation described above". It adds that "no conclusions regarding the safety or efficacy of KB801 should be drawn from it." source

   Our view: The company flagged the patent-record data itself, which is the right move. The Aug. 3 release describes EMERALD-1 without mentioning the discontinued study, and the 8-K gives no results beyond one patient, so the earlier data stay thin.

5. Legal and disclosure record · weight medium

   DOJ subpoenas, a derivative suit with a proposed settlement and a patent inventorship suit in the 10-Q

   The record says: The Q2 10-Q's legal note says the company and certain employees "received subpoenas from the U.S. Department of Justice requesting that the Company produce certain documents regarding its sponsored genetic testing program relating to VYJUVEK" and that it is cooperating. It also describes a derivative complaint filed September 18, 2025 in the Delaware Court of Chancery over director pay, with a settlement subject to a fairness hearing scheduled for September 14, 2026, and a May 29, 2026 inventorship suit by Jonathan Forman in the U.S. District Court for the District of Delaware (Docket No. 1:26-cv-00628) over patents that the plaintiff alleges are embodied in KB407. source

   Our view: The DOJ inquiry concerns the commercial practices behind the one product that generates the revenue, and the filing says no loss can be estimated. The Aug. 3 results release did not mention these matters. We did not review the later court outcome of the settlement hearing.

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our right of reply.